Leerink Swann

Leerink Swann has downgraded VIVUS (NASDAQ: VVUS) from Outperform to Market Perform.

Leerink Swann is bullish on Libigel's prospects for the treatment of female sexual dysfunction.

Leerink Swann is bullish on Libigel's prospects for the treatment of female sexual dysfunction.

Seamus Fernandez of Leerink Swann said on CNBC's Fast Money 360 that he is a buyer of Merck (NYSE: MRK) ahead of earnings. He added that Merck (MRK) is his top pick in the group, and he doesn't expect any surprises in the quarter. Carter Worth of Oppenheimer thinks that whatever happens on earnings...

In a research report released today, analysts at Leerink Swann reiterated their Market Perform rating on shares of Intuitive Surgical (NASDAQ: ISRG). The firm wrote that "ISRG continues to be a unique fast-growing, robotic surgery franchise in MedTech." Intuitive Surgical (ISRG) reported very...

Shares of Genzyme (NASDAQ: GENZ) have been volatile the last few days, after the company announced the FDA had notified them that it intends to take enforcement action to ensure that products manufactured at their plant are made in compliance with good manufacturing practice regulations. As a...

According to analysts at Leerink Swann, the Google Flu Tracker, which tracks search trends in terms of flu activity, shows a continued steep decline of 39% for the week ended March 13, as compared to the 2005-2008 flu season average. The CDC confirmed this finding on March 19, saying that there has...

Analysts Rick Wise and Danielle Antalffy at Leerink Swann have released an update on Medtronic, Inc. (NYSE: MDT). On Friday, Medtronic’s REVO MRI-Safe Pacing System was recommended for approval with conditions by a FDA panel. Analysts believe that this outcome was largely expected. According to...

Leerink Swann analysts Joshua Schimmer and Steve Y. Yoo reiterated their Outperform rating for shares of Incyte Corporation (Nasdaq: INCY) with a price target in "in the high-teens". They said that with an SPA from the FDA for the INCB18424 Phase III program, Incyte Corporation is well on its way...

Analysts Isaac Ro and Jeff Ares at Leerink Swann have released an update on Life Technologies Corp. (NASDAQ: LIFE). The company will soon launch new Attune platform for flow cytometry. Analysts believe that the launch highlights the company’s underappreciated pipeline of new products. Management...